Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Calgary, Alberta (ots/PRNewswire) -

The presentations at the ESC Congress symposium highlighted
apabetalone and the opportunity and need for a novel approach to the
treatment of high risk cardiovascular disease and diabetes.

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today
announced that on Sunday, August 28, 2016, at the European Society of
Cardiology (ESC) Congress in Rome, Italy, the Company hosted a
symposium entitled "A novel approach for high CV risk patients with
diabetes: The potential of epigenetics."

The speakers and agenda were as follows:

Introduction

Stefano Del Prato, MD - Università di Pisa, Pisa, Italy

The High Risk Diabetes patient with cardiovascular disease:
What else
can we target to reduce cardiovascular risk?
Kausik Ray, MD -
Imperial College London, United Kingdom

Understanding BET inhibition as a novel pathway for cardiovascular
risk modulation

Jorge Plutzky, MD - Brigham and Women's Hospital, Harvard Medical
School, Boston, USA

BET inhibition in cardiovascular disease: A new dawn?

John Kastelein, MD - Academic Medical Centre, Amsterdam, The
Netherlands

Discussion & summary
Stefano Del Prato, MD - Kausik Ray, MD


Presentations will be made available at: http://www.pace-cme.org.

Donald J. McCaffery, President and CEO commented, "The
presentations at the ESC Congress symposium highlighted apabetalone
and the opportunity and need for a novel approach to the treatment of
high risk cardiovascular disease and diabetes. Moreover, data
presented demonstrated the important role for epigenetics in the
underlying pathology of these diseases". McCaffrey added that "based
on its mechanism, we believe that apabetalone has the potential to
address the significant unmet medical need in this patient
population. Importantly, we remain encouraged by the recent data
safety monitoring board review and recommendation to proceed with the
BETonMACE phase 3 trial, as planned. The trial has already attained
one quarter enrollment of the planned 2,400 patients and remains on
track with internal projections."

Resverlogix also presented a poster at the congress entitled:
"Modulation of the complement cascade in cardiovascular disease
patients by a bromodomain and extraterminal (BET) protein inhibitor".
The poster will be made available on the Resverlogix website at:http:
//www.resverlogix.com/media/presentations-publications.html#.V8Lq-pgr
Khc.

The poster contained data demonstrating that apabetalone treatment
reduced basal and cytokine-induced expression of complement factors
in hepatocytes. Furthermore, in samples from CVD patients, the